--- title: "Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS" type: "News" locale: "en" url: "https://longbridge.com/en/news/295690668.md" description: "Monopar Therapeutics reported quarterly EPS of ($0.79), missing analyst estimates of ($0.66) by $0.13. Shares dipped 0.1% to $114.30. Despite the earnings miss, institutional investors including Invesco, ADAR1 Capital, and Millennium Management increased their stakes in Q4. Wall Street analysts maintain a consensus 'Buy' rating with an average price target of $112.08." datetime: "2026-08-12T16:26:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295690668.md) - [en](https://longbridge.com/en/news/295690668.md) - [zh-HK](https://longbridge.com/zh-HK/news/295690668.md) generator: "portal-rs" --- # Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.13), FiscalAI reports. Get **Monopar Therapeutics** alerts: ## Monopar Therapeutics Stock Down 0.1% - 3 Momentum Stocks Soaring Into 2025 and Beyond Shares of MNPR traded down $0.16 during mid-day trading on Wednesday, reaching $114.30. The company's stock had a trading volume of 184,271 shares, compared to its average volume of 221,278. The company has a market cap of $765.70 million, a price-to-earnings ratio of -60.16 and a beta of 1.47. Monopar Therapeutics has a 1 year low of $29.18 and a 1 year high of $124.82. The business has a fifty day moving average of $92.93 and a 200 day moving average of $70.68. ## Wall Street Analyst Weigh In A number of analysts recently commented on MNPR shares. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Monopar Therapeutics in a research report on Wednesday, July 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, BTIG Research lifted their target price on Monopar Therapeutics from $104.00 to $117.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Three investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $112.08. - MarketBeat Week in Review – 10/21- 10/25 **Read Our Latest Analysis on Monopar Therapeutics** ## Hedge Funds Weigh In On Monopar Therapeutics Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. purchased a new stake in shares of Monopar Therapeutics in the fourth quarter worth approximately $219,000. ADAR1 Capital Management LLC increased its stake in Monopar Therapeutics by 79.9% in the 4th quarter. ADAR1 Capital Management LLC now owns 233,908 shares of the company's stock valued at $15,274,000 after buying an additional 103,909 shares during the period. Virtus Investment Advisers LLC purchased a new stake in Monopar Therapeutics in the 4th quarter worth approximately $233,000. Millennium Management LLC lifted its position in Monopar Therapeutics by 945.5% in the 4th quarter. Millennium Management LLC now owns 76,674 shares of the company's stock worth $5,007,000 after buying an additional 69,340 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Monopar Therapeutics by 2.3% during the 4th quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company's stock valued at $85,908,000 after buying an additional 30,042 shares during the period. Hedge funds and other institutional investors own 1.83% of the company's stock. ## Monopar Therapeutics Company Profile (Get Free Report) - Monopar Therapeutics Skyrockets 400% on Licensing Deal Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies. The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development. ## Featured Stories - Five stocks we like better than Monopar Therapeutics - Visa’s AI Opportunity Is Hiding in Every Transaction - On Holding's Price Stumble May Be an Opening for a Company Built to Run - TSMC's 44.7% Sales Surge Signals the AI Boom Is Still Alive - CoreWeave's $129 Billion AI Backlog Changes the Bull Case *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Monopar Therapeutics Right Now? Before you consider Monopar Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list. While Monopar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [MNPR.US](https://longbridge.com/en/quote/MNPR.US.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [IVZ.US](https://longbridge.com/en/quote/IVZ.US.md) - [VRTS.US](https://longbridge.com/en/quote/VRTS.US.md) - [JHG.US](https://longbridge.com/en/quote/JHG.US.md) - [JHG.AU](https://longbridge.com/en/quote/JHG.AU.md) - [V.US](https://longbridge.com/en/quote/V.US.md) - [ONON.US](https://longbridge.com/en/quote/ONON.US.md) - [TSM.US](https://longbridge.com/en/quote/TSM.US.md) - [CRWV.US](https://longbridge.com/en/quote/CRWV.US.md) ## Related News & Research - [Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares](https://longbridge.com/en/news/297238555.md) - [Monopar cut to neutral at Cantor on valuation](https://longbridge.com/en/news/295829810.md) - [Here’s How Much You Would Have Made Owning McKesson Stock In The Last 10 Years](https://longbridge.com/en/news/297236333.md) - [The Bull Case For Otis Worldwide (OTIS) Could Change Following Tianjin 117 Sole-Provider Win - Learn Why](https://longbridge.com/en/news/297228522.md) - [BorgWarner EVP, CAO, Gen Counsel & Sec Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/296948857.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**